Marshall Wace LLP Acquires 203,361 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Marshall Wace LLP grew its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 332.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 264,523 shares of the company's stock after buying an additional 203,361 shares during the period. Marshall Wace LLP owned approximately 0.63% of SI-BONE worth $3,709,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in SIBN. American Century Companies Inc. boosted its stake in SI-BONE by 11.0% in the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock worth $33,341,000 after buying an additional 236,167 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of SI-BONE by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock worth $13,097,000 after acquiring an additional 9,847 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of SI-BONE by 35.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock worth $11,791,000 after acquiring an additional 220,555 shares during the last quarter. Impax Asset Management Group plc boosted its stake in shares of SI-BONE by 1.1% in the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock valued at $10,750,000 after purchasing an additional 8,240 shares in the last quarter. Finally, Pier Capital LLC grew its holdings in shares of SI-BONE by 1.6% during the 4th quarter. Pier Capital LLC now owns 473,123 shares of the company's stock valued at $6,633,000 after purchasing an additional 7,225 shares during the last quarter. Institutional investors own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SIBN shares. Needham & Company LLC boosted their price target on shares of SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Truist Financial reissued a "buy" rating and issued a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $24.40.

Insiders Place Their Bets

In related news, insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now directly owns 284,555 shares of the company's stock, valued at approximately $4,026,453.25. This represents a 1.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares of the company's stock, valued at approximately $3,462,574.92. The trade was a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,776 shares of company stock worth $96,644. Company insiders own 3.90% of the company's stock.

SI-BONE Trading Up 0.7 %

Shares of SIBN stock traded up $0.10 during mid-day trading on Thursday, reaching $13.75. The stock had a trading volume of 47,853 shares, compared to its average volume of 358,081. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The stock's 50-day moving average price is $14.77 and its two-hundred day moving average price is $14.65. The firm has a market capitalization of $583.73 million, a PE ratio of -14.93 and a beta of 1.02. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $19.16.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. Equities analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.